Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07701460·Not applicable·INTERVENTIONAL

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

GlucagonWeight lossNot yet recruiting

Status

Not yet recruiting

Phase

Not applicable

Enrollment

200

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Researchers at Tufts University are conducting a study to learn whether a digital lifestyle program can help people maintain their weight loss after they stop taking a GLP-1 medication. Adults who have recently stopped a GLP-1 medication may be eligible to participate. Participants will be randomly assigned to either receive access to a digital program or to continue with usual care. The study lasts 12 months and is fully remote. All participants will receive a Bluetooth scale to track weight from home and will complete short online questionnaires several times over the year. By taking part, participants can help researchers better understand how to support long-term weight maintenance in a way that is affordable, accessible, and sustainable. Participants are compensated for their time, and involvement may help improve care for others with similar experiences.

Interventions

Treatment arms and agents.

BEHAVIORAL

Digital Behavioral Application

Noom® provides well-established behavioral strategies for weight loss and weight maintenance, such as self-monitoring of diet, exercise, and weight. What Noom® adds is education on the physiological, psychological, social, and environmental factors that influence eating behavior and tools that increase self-efficacy for dealing with those stimuli. For example, Noom® has a lesson that defines social triggers, explains the influence social triggers have on motivation to eat, and asks the participant to identify their own social triggers and a plan for managing triggers should they come up. Then the app prompts participants to report back on how they managed or struggled to manage a trigger and responds accordingly. Participants will be prescribed 15 minutes of use per day per Noom® recommendations, which includes interactive lessons, food logging, and weigh-ins.

Timeline

From registration to results.

  1. First posted

    Jul 14, 2026

  2. Study start

    Aug 1, 2026

  3. Primary completion

    Jan 31, 2028

  4. Study completion

    Jul 31, 2028

  5. Results posted

    Not reported

  6. Registry updated

    Jul 16, 2026

Outcomes

What the study measures.

Primary outcomes

Percentage of weight loss maintained

Time frame · 12-months

Percentage of weight loss maintained over 12 months following GLP-1 medication cessation measured using study-provided Bluetooth scale.

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * 18 years of age or older (no upper limit); * ability to read, write, and speak English and/or Spanish; * ability to provide informed consent; * less than 30-days since GLP-1 RA cessation; * willing to participate. Exclusion Criteria: * No clinically significant weight loss (e.g., \< 5% body weight) while taking GLP medication; * major psychiatric illness, cognitive impairment, or substance misuse that could impair ability to participate; * medical conditions that significantly affect weight or make participation unsafe (e.g., pregnancy or breastfeeding, recent bariatric surgery, current use of GLP 1 or other anti-obesity medications, or endocrine disorders that alter weight regulation); * inability to use a smartphone or complete remote study procedures; * participation in another weight loss or maintenance program or clinical trial judged by investigators to interfere with study involvement; * Adults unable to consent (cognitively impaired); * Wards of the state; * Anyone under age 18.

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

This study is conducted remotely

Boston, Massachusetts, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Glucagon.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsGlucagon trial dashboard →DatabaseGlucagon database entry →ResearchGlucagon research guide →